Changes in Prevalence of Prescription Opioid Abuse after Introduction of an Abuse-Deterrent Opioid Formulation

Pain Medicine (United States)

Volumn 15, Issue 3, 2014, Pages 440-451

  Cassidy, Theresa A ^a   Dasmahapatra, Pronabesh ^a   Black, Ryan A ^a   Wieman, Matthew S ^b   Butler, Stephen F ^a  

^a INFLEXXION INC   (United States)

^b ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Abuse Deterrent Formulation; NAVIPPRO; Oxycodone; Oxymorphone; Prescription Opioid Abuse; Tamper Resistant Formulation

Indexed keywords

AMPHETAMINE; BUPRENORPHINE; COCAINE; DIAMORPHINE; OXYCODONE; OXYMORPHONE;

ADULT; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG ABUSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NARCOTIC DEPENDENCE; PRESCRIPTION; PREVALENCE; YOUNG ADULT;

ABUSE DETERRENT FORMULATION; NAVIPPRO; OXYCODONE; OXYMORPHONE; PRESCRIPTION OPIOID ABUSE; TAMPER-RESISTANT FORMULATION;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; OPIOID-RELATED DISORDERS; OXYCODONE; OXYMORPHONE; PREVALENCE; YOUNG ADULT;

EID: 84895517319     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12295     Document Type: Article

References (32)

1. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the United States, 1980-2008. [Internet]. Hyattsville, MD; 2011. Available at: http://www.cdc.gov/nchs/data/databriefs/db81.htm (accessed 11 December 2012).
2. Baldwin G. Public Health Grand Rounds: Prescription Drug Overdoses: An American Epidemic. 2011. Available at: http://www.cdc.gov/about/grand-rounds/archives/2011/01-February.htm (accessed 5 December 2012).
3. SAMSHA. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings [Internet]. 2010. Available at: http://www.samhsa.gov/data/nsduh/2k10nsduh/2k10results.htm (accessed 9 November 2012).
4. Office Of National Drug Control Policy. Epidemic: Responding to America's prescription drug abuse crisis [Internet]. Pharmaceutical Marketing. 2011. p. 10. Available from: http://www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf (accessed 9 November 2012).
5. Katz N. Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep 2008;10:11-18.
6. Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J 2009;6:8.
7. Butler SF, Cassidy TA, Chilcoat H, etal. Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14(4):351-358.
8. Cicero TJ, Ellis MS, Surratt H. Effect of abuse-deterrent formulation of OxyContin. NEJM 2012;367:187-189.
9. Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs 2010;70(13):1657-1675.
10. IMS Health Inc. Vector One: National (VONA), 2011.
11. Butler S, Budman S, Licari A, etal. National addictions vigilance intervention and prevention program (NAVIPPRO): A real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008;17(12):1142-1154.
12. Hendricks V, Kaplan C, VanLimbeek J, Geerlings P. The addiction severity index: Reliability and validity in a Dutch addict population. J Subst Abuse Treat 1989;6:133-141.
13. Kosten T, Rounsaville B, Kleber H. Concurrent validity of the addiction severity index. J Nerv Ment Dis 1983;171(10):606-610.
14. McLellan A, Luborsky L, Woody G, O'Brien C. An improved evaluation instrument for substance abuse patients: The Addiction Severity Index. J Nerv Ment Dis 1980;168:26-33.
15. McLellan AT, Kushner H, Metzger D, etal. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992;9(3):199-213.
16. Butler S, Budman S, Goldman R, etal. Initial validation of a computer-administered addiction severity index: The ASI-MV. Psychol Addict Behav 2001;15(1):4-12.
17. Butler SF, Redondo JP, Fernandez KC, Villapiano A. Validation of the Spanish Addiction Severity Index Multimedia Version (S-ASI-MV). Drug Alcohol Depend 2009;99(1-3):18-27.
18. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011;8(1):29. BioMed Central Ltd.
19. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159(7):702-706.
20. SAS® 9.3 System Options: Reference, Second edition. 2011.
21. Joinpoint Regression Program, Version 3.5. Statistical Methodology and Applications Branch and Data Modeling Branch, Surveillance Research Program National Cancer Institute. 2012.
22. Hays L. A profile of OxyContin addiction. J Addict Dis 2008;23(4):1-9.
23. Butler S, Black R, Serrano J. Characteristics of prescription opioid abusers in treatment: Prescription opioid use history, age, use patterns, and functional severity. J Opioid Manag 2010;6(4):239-252. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20862904 (accessed 11 December 2012).
24. Schneider J, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations. What is their role in addressing prescription opioid abuse? CNS Drugs 2010;10:805-810.
25. Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis 2007;26(3):107-111.
26. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007;88(1):75-78.
27. Johanson C, Arfken C, Di Menza S, Schuster C. Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians. Drug Alcohol Depend 2012;120:190-195.
28. Carise D, Dugosh K, McLellan A, etal. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 2007;164(11):1750-1756.
29. Katz N, Dart RC, Bailey E, etal. Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011;37(4):205-217.
30. Green TC, Black R, Grimes Serrano JM, Budman SH, Butler SF. Typologies of prescription opioid use in a large sample of adults assessed for substance abuse treatment. PLoS ONE 2011;6(11):e27244.
31. Katz N, Fernandez K, Chang A, Benoit C, Butler S. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain 2008;24(6):528-535.
32. Vosburg SK, Jones JD, Manubay JM, etal. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend 2012;126(1-2):206-215.